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Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia which is often asymptomatic AF. 
years of the follow-up), the overall incidence for major bleeding in the anticoagulated population appeared to be as high as 2.1 (ranging 0.9-3.4) for controlled trials and 2.0 (ranging 0.2-7.6) for observational studies. [7] Therefore, stroke risk assessment should also be accompanied with an appraisal of patient's bleeding risk. [2] Nonetheless, stroke and bleeding risk track each other, and many risk factors for stroke are also risk factors for bleeding. [6] Amongst the different bleeding risk scores ,only three (HEMORR 2 HAGES, HAS-BLED and ATRIA) were derived and validated in patients with AF. [6] The HAS-BLED score is recommended in the ESC, Canadian Cardiovascular Society and NICE guidelines for assessing bleeding risk in AF. An assessment of the net clinical benefit shows a positive net clinical benefit for OAC for most patients with ≥1 stroke risk factors given that the gain from reducing strokes outweighs the small increase in serious bleeding risk. [8] In the current issue of Thrombosis Research, Barnes et al. [9] These results are consistent with previous similar studies, showing that specific bleeding risk scores perform best in predicting bleeding, compared to using CHADS 2 or CHA 2 DS 2 -VASc.
[ [10] [11] [12] In the post-hoc analysis of the AMADEUS trial cohort, the HAS-BLED score but not the CHADS 2 and CHA 2 DS 2 -VASc scoring systems demonstrated significant discriminatory performance for any clinically relevant bleeding (major and non-major). [11] Broadly similar data were obtained in the study of Roldán et al, who followed-up 1370 'real world' (ie. nontrial) AF patients in an outpatient anticoagulation clinic for median of 996 days. [12] Barnes et al. also suggest considering an integration of both stroke and bleeding risk assessment schemes into a single risk assessment score [9] . Perhaps this is unwise. The current experience of the development of combination (or composite) stroke and bleeding risk assessment scores testifies to their complexity and only marginal comparative performance against the currently recommended individual stroke and bleeding stratification schemes. [13, 14] In one study from the AMADEUS trial cohort, regression models for composite end-points 'stroke/thromboembolism or major bleeding' and 'stroke, systemic or venous embolism, myocardial infarction, cardiovascular death, or major bleeding' included following predictors: age, previous stroke / transient ischaemic attack, aspirin use, time in therapeutic range and left ventricular dysfunction (the latter had predictive value for second end-point only), but despite good predictive value for the composite endpoint, did not offer significant
advantage over separate stroke and/or bleeding risk scores. [13] In the Loire Valley Atrial Fibrillation Project, a composite risk model included risk factors from the HAS-BLED and CHA 2 DS 2 -VASc scores (history of heart failure, age >75, age >65, diabetes mellitus, stroke, vascular disease, liver and/or renal impairment, history of bleeding and labile international normalized ratio) and was tested for four end-points, but also failed to outperform separate stroke and bleeding risk assessment scores. [14] Nonetheless, another important aspect of study of Barnes et al. is a validation of the bleeding risk assessment schemes in their studied cohort. [9] They highlighted a modest predictive ability of existing bleeding scores as evaluated with the c-statistic, which is a statistical index used to compare performance of different prognostic tools with range between 0.5 (model is not better than chance at making prediction) and 1.0 (perfect prediction with the model).
For risk scores to be useful for everyday clinical practice, one has to reduce complexity and increase simple practicality of the risk assessment tools (importantly, without loss of their discriminative ability). Also, equal weighing is assigned for majority of risk factors (i.e., 1 point for each) for simplicity -despite the fact that in the derivation studies, the association of various risk factors with predicted outcomes varied in wide range. Thus, a c-statistic of 1.0 cannot be reached, without exceedingly complex and impractical risk stratification schemes that include a long list of clinical factors added to biomarkers, imaging etc. [6] Nevertheless, previous studies have shown that the HAS-BLED score outperformed older bleeding risk scores and the newer ATRIA bleeding score, and HAS-BLED was the only score A C C E P T E D M A N U S C R I P T 
